Sep 24, 2007- Press Release
Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Aug 27, 2007- Press Release
Adnexus Therapeutics Announces Additional Phase I and Preclinical
Data on CT-322 at 6th International Congress on Targeted Therapies in Cancer
Aug 21, 2007- Press Release
Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering
Aug 21, 2007- Press Release
Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors
Aug 20, 2007- Press Release
Adnexus Therapeutics to Present Data on Adnectin Product Candidate, CT-322, at Gordon Research Conference
Aug 9, 2007- Press Release
Adnexus Therapeutics Raises $15.5 Million in Series C Funding
July 11, 2007- Press Release
Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer
April 17, 2007- Press Release
Adnexus Therapeutics Announces Presentation at The American Association For Cancer Research (AACR) on Clinical Product Candidate, CT 322
February 26, 2007- Press Release
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
February 2, 2007- Press Release
Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans
November 28, 2006 - Press Release
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
November 1, 2006 - Press Release
Adnexus Therapeutics to Present at Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6th
October 23, 2006 - Press Release
Adnexus Therapeutics Announces Issuance of U.S. Patent For Broad Protection of New Therapeutic Class, Adnectins™
September 26, 2006 - Press Release
Adnexus Therapeutics Appoints L. Patrick Gage, PH.D., As Chairman Of The Board Of Directors
September 25, 2006 - Press Release
Adnexus Therapeutics To Present At UBS Global Life Sciences Conference On Tuesday, September 26
September 5, 2006 - Press Release
Adnexus Therapeutics to Present at Thomas Weisel Partners Healthcare Conference
September 5, 2006 - Press Release
Adnexus Therapeutics Awarded SBIR Grant for Adnectin Research
September 5, 2006 - Press Release
Adnexus Therapeutics Expands and Strengthens Senior Management Team
June 26, 2006 - Press Release
Adnexus Therapeutics Closes $27M Series B Funding
June 21, 2006 - Press Release
First Adnectin Therapeutic, CT-322, Clears FDA IND Review To Start Clinical Trials
June 21, 2006 - Press Release
Compound Therapeutics Becomes Adnexus Therapeutics
June 22, 2005 - Press Release
Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies With Lead Oncology Product
June 15, 2005 - Press Release
Compound Therapeutics Appoints Dr. John Mendlein as CEO
January 18, 2005 - Press Release
Compound Therapeutics, Inc. Raises $15.5 Million To Advance Product Pipeline Into Clinic
